

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/526,072
Filing Date	February 28, 2005
First Named Inventor	K. SUGIMURA et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	SUGIMURA=4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
I.Z.S./	AA	Dictionary of Immunology, 1 st edition, page 49, 1993 (2 nd edition, page 60).	
	AB	S. AKIRA et al; "Interleukin-6 in Biology and Medicine"; <i>Advances in Immunology</i> , Vol. 54, pages 1-78; 1993.	
	AC	R. GEJIMA et al; "Human Single-chain FV (scFv) Antibody Specific to Human IL-6 with the Inhibitory Activity on IL-6-signaling"; <i>Human Antibodies</i> ; Vol. 11(4), pages 121-129; 2002.	
	AD	T. HIRANO et al; "Interleukin-6: Possible Implications in Human Diseases"; <i>Res. Clin. Lab.</i> , Vol. 19(1), pp. 1-10; 1989.	
	AE	B. KREBS et al; "Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6"; <i>The Journal of Biological Chemistry</i> ; Vol. 273(5), pp. 2858-2865; 1998.	
	AF	J. D. MARKS et al; "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage "; <i>Journal Molecular Biology</i> ; Vol. 222(3); pp. 581-597; 1991.	
	AG	M. MIHARA et al; "Interleukin-6 (IL-6) Induces the proliferation of Synovial Fibroblastic Cells in the Presence of Soluble IL-6 Receptor; <i>British Journal of Rheumatology</i> "; Vol. 34(4); pp. 321-325; 1995.	
	AH	M. MIHARA et al; "Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys"; <i>Clinical Immunology</i> "; Vol. 98(3); pp. 319-326; 2001.	
	AI	S. MONIER et al; "Growth Factor Activity of IL-6 in the Synovial fluid of patients with rheumatoid arthritis"; <i>Clinical and Experimental Rheumatology</i> ; Vol. 12(6); pp. 595-602, 1994.	
	AJ	F. MONTERO-JULIAN et al; "Pharmacokinetic Study of Anti-Interleukin-6 (IL-6) Therapy with Monoclonal Antibodies: Enhancement of IL-6 Clearance by Cocktails of Anti-IL-6 Antibodies"; <i>Blood</i> ; Vol. 85; pp. 917-924; 1995.	
	AK	N. NISHIMOTO et al; "Clinical Application of Interleukin-6 receptor antibody"; <i>Japanese Society for Immunology</i> ; Vol. 20 (2); pp. 87-94; 1997.	
	AL	A. OGATA et al; "Advances in Interleukin-6 Therapy"; <i>Clinical Pathology</i> ; Vol. 47(4); pp. 321-326, 1999.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	10/526,072
Filing Date	February 28, 2005
First Named Inventor	K. SUGIMURA et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	SUGIMURA=4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/Z.S./	AM	K. SATO et al; "Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region"; <i>Human Antibody Hybridomas</i> ; Vol. 7(4), pp. 175-193; 1996.	
/Z.S./	AN	D. WENDLING et al; "Treatment of Severe Rheumatoid Arthritis by anti-interleukin 6 monoclonal antibody"; <i>Journal Rheumatology</i> ; Vol. 20(2); pp. 259-262; 1993.	
/Z.S./	AO	J. WIJDENES et al "Human Recombinant Dimeric IL-6 Binds to Its Receptor as Detected by Anti-IL-6 Monoclonal Antibodies"; <i>Molecular Immunology</i> ; Vol. 28(11), pages 1183-1192; 1991.	
/Z.S./	AP	G. VREUGDENHIL et al; "Anaemia of chronic disease in rheumatoid arthritis"; <i>Rheumatol Int.</i> , Vol. 10 (3), pp. 127-130; 1990.	

Examiner
Signature

/Zachary Skelding/

Date
Considered

10/05/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/526,072
Filing Date	February 28, 2005
First Named Inventor	K. SUGIMURA et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	SUGIMURA-4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)				
/Z.S./	AQ	WO 2005/105998 A	11-10-2005	JURIDICAL FOUNDATION THE CHEMO-SERO- THERAPEUTIC RESEARCH INSTITUTE		Abs

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

Examiner
Signature

/Zachary Skelding/

Date
Considered

10/05/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.